Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Price | Value | Graham Fair Value | Graham Fair Value % | P/E | Forward P/E | P/S | P/B | PEG | Free Cash Flow | Free Cash Flow Yield | Book Value | BVPS | EV | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $347.72 | $7.26 | 4,690.69% | 6,954.40x | 334.31x | 7.70x | 9.33x | 18.59x | $529.27M | 1.38% | $4.13B | 37.48 | $36.38B | 114.41 | ||
| CORT | CORCEPT THERAPEUTICS INC | $77.29 | $32.60 | 137.12% | 77.29x | 75.96x | 10.80x | 12.87x | 1.08x | $162.57M | 2.03% | $631.90M | 6.10 | $8.01B | 121.42 | ||
| NVO | NOVO NORDISK A S | $47.63 | $151.01 | -68.46% | 13.25x | 1.99x | 4.35x | 8.08x | 0.14x | $9.34B | 4.41% | $26.18B | 5.89 | $222.30B | 8.96 | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $436.38 | $28.94 | 1,407.97% | 1,407.68x | 299.73x | 17.87x | 246.49x | 5.99x | $221.36M | 0.39% | $233.89M | 1.78 | $59.37B | 390.82 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $1.75 | $4.99 | -64.91% | 25.00x | 13.33x | 2.24x | 2.66x | 0.14x | -$11.69M | -8.40% | $52.91M | 0.67 | $135.27M | 15.25 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $8.60 | $11.28 | -23.76% | 17.92x | 7.01x | 5.70x | 3.64x | 0.38x | -$23.64M | -4.92% | $133.17M | 2.38 | $492.44M | 7.33 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $41.58 | $15.09 | 175.57% | 84.86x | 39.29x | 5.20x | 5.89x | 1.27x | $101.73M | 3.28% | $535.38M | 7.17 | $2.99B | 55.74 | ||
| VCEL | VERICEL CORP | $39.58 | $7.27 | 444.65% | 152.23x | 176.38x | 7.72x | 6.22x | 2.56x | $20.38M | 1.02% | $321.86M | 6.38 | $2.00B | 68.21 | ||
| ARGX | ARGENX SE | $918.92 | $257.47 | 256.90% | 36.72x | 54.91x | 29,642.58x | 7.82x | 3.07x | $467.72M | 0.83% | $7.17B | 117.50 | $53.68B | 66.17 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $199.23 | $61.39 | 224.51% | 86.25x | 28.45x | 15.53x | 4.13x | 1.55x | $30.76M | 0.79% | $950.17M | 48.53 | $4.23B | 41.09 | ||
| GMAB | GENMAB A | $30.45 | $114.38 | -73.38% | 13.00x | 1.76x | 5.49x | 3.40x | 0.11x | $1.19B | 6.11% | $5.75B | 8.96 | $17.93B | 8.96 | ||
| RPRX | ROYALTY PHARMA PLC | $38.92 | $41.63 | -6.51% | 22.11x | 8.49x | 7.15x | 2.34x | 0.46x | $2.11B | 12.56% | $9.62B | 22.28 | $30.47B | 29.18 | ||
| TECH | BIO-TECHNE CORP | $61.53 | $16.24 | 278.92% | 123.06x | 30.11x | 7.86x | 4.88x | 1.72x | $224.06M | 2.34% | $1.97B | 12.65 | $9.84B | 44.53 | ||
| KRYS | KRYSTAL BIOTECH INC | $212.02 | $83.92 | 152.64% | 30.73x | 41.62x | 16.45x | 5.40x | 1.81x | $166.02M | 2.70% | $1.14B | 39.30 | $5.76B | 29.82 | ||
| CRMD | CORMEDIX INC | $9.68 | $16.60 | -41.70% | 4.26x | 4.57x | 3.43x | 2.04x | 1.08x | $74.42M | 10.12% | $374.13M | 4.93 | $863.11M | 7.69 | ||
| MDXG | MIMEDX GROUP INC | $6.76 | $3.61 | 87.23% | 24.14x | 15.59x | 2.54x | 4.19x | 1.27x | $66.82M | 6.67% | $238.95M | 1.61 | $877.30M | 12.68 | ||
| GYRE | GYRE THERAPEUTICS INC | $7.55 | $0.85 | 785.23% | 107.86x | 71.63x | 6.39x | 7.14x | 6.33x | $3.05M | 0.45% | $101.92M | 1.12 | $688.08M | 52.01 | ||
| VCYT | VERACYTE INC | $44.01 | $8.89 | 395.21% | 112.85x | 110.16x | 7.00x | 2.77x | 2.48x | $98.21M | 2.84% | $1.26B | 15.98 | $3.20B | 56.18 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $54.69 | $41.91 | 30.51% | 20.11x | 18.01x | 3.39x | 1.73x | 0.78x | $832.13M | 7.92% | $6.06B | 31.54 | $9.85B | 12.75 | ||
| HALO | HALOZYME THERAPEUTICS INC | $70.34 | $76.82 | -8.43% | 14.38x | 11.20x | 6.63x | 16.42x | 0.54x | $602.40M | 7.31% | $503.92M | 4.30 | $9.36B | 11.07 | ||
| INVA | INNOVIVA INC | $20.96 | $18.18 | 15.28% | 11.09x | 17.61x | 3.73x | 1.55x | 1.09x | $196.54M | 13.58% | $1.01B | 14.63 | $1.35B | 6.28 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $426.76 | $172.77 | 147.00% | 29.82x | 23.22x | 9.30x | 6.25x | 1.78x | $3.34B | 3.06% | $17.32B | 67.76 | $105.17B | 22.56 | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $15.68 | $7.13 | 119.90% | 27.03x | 23.71x | 7.77x | 5.65x | 1.56x | $119.87M | 5.80% | $365.77M | 2.78 | $2.07B | 20.02 | ||
| EXEL | EXELIXIS INC | $42.51 | $27.23 | 56.12% | 17.28x | 17.73x | 4.99x | 5.27x | 1.23x | $779.77M | 6.83% | $2.16B | 8.05 | $11.20B | 12.07 | ||
| ADMA | ADMA BIOLOGICS INC | $17.18 | $9.29 | 85.02% | 19.52x | 28.39x | 8.39x | 9.48x | 1.54x | $40.73M | 1.00% | $431.19M | 1.81 | $4.10B | 23.83 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $34.31 | $39.63 | -13.42% | 10.62x | 10.50x | 2.39x | 2.37x | 0.62x | $296.89M | 15.04% | $835.12M | 14.51 | $1.50B | 5.55 | ||
| INCY | INCYTE CORP | $102.06 | $66.90 | 52.55% | 16.90x | 14.65x | 4.15x | 4.31x | 1.20x | $1.20B | 5.99% | $4.65B | 23.77 | $17.62B | 10.47 | ||
| UTHR | UNITED THERAPEUTICS CORP | $474.82 | $193.79 | 145.02% | 16.67x | 16.91x | 6.65x | 3.10x | 6.44x | $1.12B | 5.39% | $6.59B | 150.46 | $19.10B | 10.77 | ||
| MNKD | MANNKIND CORP | $5.03 | $1.28 | 294.26% | 50.30x | 53.12x | 4.92x | -34.67x | 2.71x | $43.39M | 2.80% | -$44.55M | -0.15 | $1.78B | 24.28 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $755.90 | $349.48 | 116.29% | 17.40x | 17.68x | 5.50x | 2.57x | 2.94x | $4.22B | 5.39% | $30.96B | 298.82 | $79.64B | 13.94 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $23.28 | $10.85 | 114.57% | 13.01x | 15.65x | 4.94x | 3.11x | 21.95x | $234.54M | 8.22% | $920.25M | 7.51 | $2.17B | 6.71 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.